Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe abdomen, the outer thigh, and the upper arm are the three licensed injection sites for Mounjaro (tirzepatide) in the UK. Each delivers the medicine effectively, and the clinical evidence does not single out one site as meaningfully superior to the others for weight loss — but rotating between them matters more than most people realise. These are prescription-only medicines requiring clinical assessment before starting, and the detail below is educational: your prescriber and the Patient Information Leaflet are always your primary guides. If you are already using Mounjaro and want to refine your injection technique for weight loss, the facts below should help.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most common question our prescribers field about injection sites is some version of: "Will I lose more weight if I inject into my stomach rather than my thigh?" The short answer is no. There is no clinical evidence from the SURMOUNT trials (the phase 3 programme in which thousands of adults with obesity took tirzepatide) that any of the three licensed sites produces meaningfully different weight-loss results. The medicine is absorbed subcutaneously in all three locations, and the pharmacokinetic profile of the KwikPen is designed to work across them consistently. Mounjaro's mechanism (dual GIP and GLP-1 receptor agonism) is systemic: once it reaches the bloodstream, the signal travels to the brain and gut regardless of where it was deposited. What does affect absorption (and therefore real-world results) is site rotation, skin condition, and technique. So if you have been favouring one spot week after week because it feels easier, that is the habit worth changing, not the site itself.
The full guide to Mounjaro injection sites covers each location in more practical depth if you want to compare positioning and technique.
Rotating your injection site is not a box-ticking exercise. Used repeatedly in the same small patch of skin, GLP-1 medicines can cause lipohypertrophy: the tissue thickens and hardens, forming a lump that looks innocuous but absorbs medicine irregularly. You may get less tirzepatide into circulation than the dose on the pen suggests, which can blunt the appetite-suppressing effect or cause unexpected nausea spikes. The fix is straightforward: move at least 1–2 cm from your last injection point, and cycle through different areas of the same site (upper vs. lower abdomen, left vs. right thigh, alternating arms) rather than returning to exactly the same spot every week.
A practical method some of our patients find useful: note which site you used on your phone or a calendar, the same way you might track your weekly dose. If your injections land on a Monday (many people choose their injection day to align with a weekly routine, which also makes it easier to remember around bank holidays or a holiday abroad) then a quick note in your calendar each time keeps the rotation honest. There is more detail on exactly where to position each injection if you want a site-by-site breakdown.
Clean the skin with an alcohol swab before injecting. If you need a reliable supply, alcohol swabs are available from our pharmacy alongside your treatment.
Abdomen. Most people find the abdomen easiest to reach and visualise. Avoid the 5 cm ring immediately around the navel, the skin there is thicker and the tissue less predictable. The injection should go into the subcutaneous fat layer, which in most adults sits just below the surface across the lower and lateral abdomen. Pinching a fold of skin gently can help if you are lean.
Outer thigh. The upper outer quadrant of the thigh works well and is easy to access when sitting. Avoid the inner thigh (too much friction and movement) and avoid injecting directly over the knee or hip bone. Some people find the thigh slightly more comfortable than the abdomen, particularly in the first few weeks at the 2.5 mg dose.
Upper arm. The back or outer aspect of the upper arm is the third licensed site. It requires either a mirror or a second person, self-administering into the back of the arm solo is awkward and risks a shallow or off-angle injection. It is the least-used site as a primary location but a valid option for rotation, particularly for those who travel and find the arm easiest in a small space.
Whatever site you choose, the NHS guidance on tirzepatide administration and the Mounjaro Patient Information Leaflet (available via the eMC) contain the canonical technique instructions. If you are considering starting treatment, our Mounjaro injection guide walks through each step.
Most injection-site reactions (a little redness, mild itching, or brief tenderness) settle within a day or two and do not need urgent attention. If you notice a lump that persists across several weeks, skin that feels noticeably harder in one area, or a reaction that spreads or worsens, tell your prescriber at your next review. Do not simply avoid that patch and carry on; repeated nearby injections will compound the problem.
Genuine allergic reactions are uncommon but worth recognising: widespread rash, swelling, difficulty breathing, or feeling faint after an injection are reasons to seek medical help promptly, not to wait for your next scheduled call. You can also report any unexpected reactions via the MHRA's Yellow Card scheme, which helps regulators monitor the medicine's real-world safety profile.
If something does not feel right about your injection routine, changing it is simpler than you might think. You can revisit your injection timing alongside your site choices as part of the same conversation with your prescriber. For a broader look at weight management options, our treatment overview sets out what is available. Ready to start or continue with clinical support? Speak to our prescribers, your consultation is free and reviewed the same day by a GPhC-registered Independent Prescriber.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.